

S1 Table. Clinical variables classified according to the administration of renin-angiotensin system (RAS) blockers

| | RAS blockers (+) (N = 255, 73.5%) | RAS blockers (-) (N = 92, 26.5%) | Total (N = 347) | P |
|---|--|---|----------------------------------|----------|
| Age (years) | 39 (31, 49) | 30 (21, 43) | 37 (29, 48) | <0.001 |
| Male (n/%) | 111/43.5% | 37/40.2% | 148/42.7% | 0.582 |
| Smoker (n/%) | 33/12.9% | 6/6.5% | 39/11.2% | 0.095 |
| Diabetes mellitus (n/%) | 11/4.3% | 2/2.2% | 13/3.7% | 0.354 |
| Body mass index (kg/m²) | 23.1 (20.7, 24.9) | 21.5 (19.6, 24.2) | 22.6 (20.5, 24.8) | <0.001 |
| Systolic blood pressure (mmHg) | 126 (115, 140) | 120 (110, 130) | 124 (111, 140) | <0.001 |
| Microscopic hematuria (n/%) | 228/89.4% | 83/90.2% | 311/89.6% | 0.828 |
| UPCR (g/g) | 1.06 (0.50, 2.28) | 0.57 (0.21, 1.02) | 0.91 (0.43, 1.97) | <0.001 |
| Serum creatinine (mg/dL) | 1.0 (0.8, 1.3) | 0.9 (0.8, 1.1) | 1.0 (0.8, 1.3) | 0.019 |
| eGFR (mL/min/1.73 m²) | 70.4 (52.7, 88.1) | 82.3 (60.0, 97.2) | 74.2 (54.2, 90.8) | 0.002 |
| Serum albumin (mg/dL) | 4.0 (3.7, 4.3) | 4.1 (3.7, 4.4) | 4.0 (3.7, 4.3) | 0.155 |
| Serum IgA (mg/dL) | 291.0 (234.0, 365.5) | 273.0 (173.0, 341.0) | 283.0 (222.3, 358.5) | 0.005 |
| Uric acid (mg/dL) | 5.8 (4.6, 7.1) | 4.9 (4.2, 6.0) | 5.5 (4.4, 6.9) | 0.002 |
| Circulating TNFR1 (pg/mL) | 1148.5 (819.9, 1513.2) | 897.0 (597.3, 1339.8) | 1077.8 (746.8, 1470.9) | 0.001 |
| Circulating TNFR2 (pg/mL) | 2623.1 (1991.4, 3809.9) | 2080.4 (1710.9, 3114.6) | 2412.3 (1896.0, 3568.8) | 0.002 |
| Glomerular sclerosis | | | | 0.360 |
| None | 108/42.4% | 42/45.7% | 150/43.2% | |
| Mild | 103/40.4% | 36/39.1% | 139/40.1% | |
| Moderate | 23/9.0% | 11/12.0% | 34/9.8% | |
| Severe | 21/8.2% | 3/3.3% | 24/6.9% | |
| Mesangial hypercellularity | | | | <0.001 |
| None | 14/5.5% | 18/19.6% | 32/9.2% | |
| Mild | 154/60.4% | 63/68.5% | 217/62.5% | |
| Moderate | 41/16.1% | 8/8.7% | 49/14.1% | |

| | | | | |
|--|-----------|----------|-----------|--------|
| Severe | 46/18.0% | 3/3.3% | 49/14.1% | |
| Interstitial fibrosis/tubular atrophy | | | | 0.124 |
| None | 47/18.4% | 21/22.8% | 68/19.6% | |
| Mild | 155/60.8% | 62/67.4% | 217/62.5% | |
| Moderate | 43/16.9% | 7/7.6% | 50/14.4% | |
| Severe | 10/3.9% | 2/2.2% | 12/3.5% | |
| Crescent formation | | | | 0.646 |
| None | 199/78.0% | 74/80.4% | 273/78.7% | |
| Mild | 49/19.2% | 17/18.5% | 66/19.0% | |
| Moderate | 7/2.7% | 1/1.1% | 8/2.3% | |
| Medical treatment (n/%) | | | | |
| Statin | 77/30.2% | 4/4.3% | 81/23.3% | <0.001 |
| Immunosuppressant | 36/14.1% | 7/7.6% | 43/12.4% | 0.104 |

Data are presented as a number (percent) or a median (25th, 75th percentiles).

eGFR, estimated glomerular filtration rate; TNFR, tumor necrosis factor receptor; UPCR, urine protein-creatinine ratio